United States: Are Secret Sales Prior Art Under The AIA?

In Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., the Federal Circuit found that a publicly-announced "Supply and Purchase" agreement triggered the on-sale bar under pre-AIA 35 USC § 102(b) and under AIA 35 USC § 102(a)(1). With this case, the court offered its first interpretation of the on-sale bar of the America Invents Act. Although the court did not address whether an entirely secret sale would qualify as prior art under the AIA, it decided that where the existence of the sale was made known to the public, the sale constitutes prior art even if the public disclosure did not reveal the invention.

The Patents At Issue

The patents before the court included three pre-AIA patents and one AIA patent. The pre-AIA patents were U.S. Patent Nos. 7,947,724, 7,947,725, and 7,960,424. The Court identified claim 2 of the '725 patent as representative of the group.

  1. A pharmaceutically stable solution for reducing emesis or reducing the likelihood of emesis comprising:

    1. 0.05 mg/mL palonosetron hydrochloride, based on the weight of the free base, in a sterile injectable aqueous carrier at a pH of from 4.5 to 5.5;
    2. from 0.005 mg/mL to 1.0 mg/mL EDTA; and
    3. mannitol in an amount sufficient to tonicify said solution, in a concentration of from about 10 mg/ml to about 80 mg/ml.

The AIA patent was U.S. Patent No.8,598,219. The court identified claim 1 as representative:

  1. A pharmaceutical single-use, unit-dose formulation for intravenous administration to a human to reduce the likelihood of cancer chemotherapy-induced nausea and vomiting, comprising a 5 mL sterile aqueous isotonic solution, said solution comprising:

    • palonosetron hydrochloride in an amount of 0.25 mg based on the weight of its free base;
    • from 0.005 mg/mL to 1.0 mg/mL EDTA; and
    • from 10 mg/mL to about 80 mg/mL mannitol,
    • wherein said formulation is stable at 24 months when stored at room temperature.

The Agreements At Issue

In April 2001, almost two years before applying for the patents, Helsinn and a third party company (MGI) entered into two agreements: (1) a License Agreement and (2) a Supply and Purchase Agreement. The agreements related to 0.25 mg and 0.75 mg doses of the palonosetron products, or for whichever of the two dosages were approved by the FDA.

The agreements were announced in a joint press release and in a filing with the Securities and Exchange Commission, which included partially-redacted copies of both agreements. However, two features of the agreements were not publicly disclosed: (1) the price terms and (2) the specific dosage formulations covered by the agreements (i.e., the 0.25 and 0.75 mg doses).

The district court found the agreements qualified as a "sale" under pre-AIA § 102(b), but did not render the pre-AIA patents invalid because the invention was not yet "ready for patenting" because FDA approval had not been obtained. With regard to the AIA patent, the district court found the agreements did not qualify as a "sale" under AIA § 102(a)(1), interpreting that statute as requiring a sale to "publicly disclose the details of the invention," which was not the case here.

The On-Sale Bar Under Medicines Co.
(Pre-AIA 35 USC § 102(b))

The Federal Circuit decision was authored by Judge Dyk and joined by Judges Mayer and O'Malley. The court addressed whether the agreements triggered the on-sale bar under either statute, and whether the invention was sufficiently ready for patenting prior to the critical date in order for the sales to be invalidating.

With regard to the pre-AIA patents, the Federal Circuit found the Supply and Purchase Agreement to amount to an invalidating sale under pre-AIA § 102(b), applying the analytical framework established in Medicines Co. v. Hospira, Inc., 827 F.3d 1363 (Fed. Cir. 2016) (en banc). As stated by the court:

The Supply and Purchase Agreement bears all the hallmarks of a commercial contract for sale. It obligated MGI to purchase exclusively from Helsinn and obligated Helsinn to supply MGI's requirements of the 0.25 and 0.75 mg doses if approved by FDA.

The court explained that the existence of a sale was not altered by the uncertainty as to whether the FDA would approve the 0.25 mg dose or the 0.75 mg dose, finding FDA approval to be a condition precedent to the sale. The court also explained that the agreement was not too uncertain to constitute a sale simply because it covered the 0.25 mg dose, the 0.75 mg dose, and both doses.

The court noted that it was not creating a rule that all distribution agreements constitute sales under § 102(b), but distinguished Medicines Co. along these lines:

Helsinn did not contract for MGI's confidential marketing or distribution services as Medicines contracted for Ben Venue's confidential manufacturing services. Instead, the Supply and Purchase Agreement between Helsinn and MGI unambiguously contemplated the sale by Helsinn of MGI's requirements of the claimed invention.

The On-Sale Bar Under The AIA
(AIA 35 USC § 102(a)(1)

With regard to the AIA patent, the court reversed the district court and held that the Supply and Purchase Agreement met the requirements of the on-sale bar under the AIA.

After the AIA, if the existence of the sale is public, the details of the invention need not be publicly disclosed in terms of the sale" to meet the requirements of the on-sale bar.

The language of AIA 35 USC § 102(a)(1) at issue reads:

A person shall be entitled to a patent unless [] the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.

Teva and various amici argued that the AIA did not change the on-sale bar, since Congress used the same "on sale" term in AIA § 102(a)(1) that appears in pre-AIA § 102(b). On the other hand, Helsinn, the U.S. government, and other amici argued that the AIA did change the law by adding the catch-all provision, "or otherwise available to the public," which they argued reflects back on the "on sale" clause and requires any "sale" to make the invention "available to the public."

The court reviewed the language of the statute and legislative history alleged to support a change in the law, and concluded that there was no indication in the cited floor statements that reflected Congressional intent to change the law and overrule existing on-sale bar jurisprudence. The court therefore held:

[A]fter the AIA, if the existence of the sale is public, the details of the invention need not be publicly disclosed in the terms of sale.

Thus, even though specific details of the Helsinn invention were not made public by the announcement of the agreements, since their existence was made public the on-sale bar was triggered under AIA § 102(a)(1).

The court also reversed the district court's "not ready for patenting" ruling, emphasizing that "[t]he completion of Phase III studies and final FDA approval are not prerequisites for the invention here to be ready for patenting, and finding "overwhelming" evidence "that before the critical date ... it was established that the patented invention would work for its intended purpose."

Avoiding Prior Art Under The AIA

Although some were hoping the AIA would do away with secret prior art, the court's decision that the AIA did not drastically change the on-sale bar lends more predictability to this area of law. The court's ruling on the "ready for patenting" issue is a good reminder of the tensions between filing a patent application early enough to avoid prior art but late enough to be able to provide an enabling disclosure.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.